IBDEI142 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18551,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,18551,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,18552,0)
 ;;=E10.618^^94^908^5
 ;;^UTILITY(U,$J,358.3,18552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18552,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Arthropathy
 ;;^UTILITY(U,$J,358.3,18552,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,18552,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,18553,0)
 ;;=E10.621^^94^908^7
 ;;^UTILITY(U,$J,358.3,18553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18553,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,18553,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,18553,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,18554,0)
 ;;=E10.622^^94^908^11
 ;;^UTILITY(U,$J,358.3,18554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18554,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,18554,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,18554,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,18555,0)
 ;;=E10.65^^94^908^10
 ;;^UTILITY(U,$J,358.3,18555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18555,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycermia
 ;;^UTILITY(U,$J,358.3,18555,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,18555,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,18556,0)
 ;;=E10.39^^94^908^9
 ;;^UTILITY(U,$J,358.3,18556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18556,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Ophthalmic Complications NEC
 ;;^UTILITY(U,$J,358.3,18556,1,4,0)
 ;;=4^E10.39
 ;;^UTILITY(U,$J,358.3,18556,2)
 ;;=^5002603
 ;;^UTILITY(U,$J,358.3,18557,0)
 ;;=E66.3^^94^908^45
 ;;^UTILITY(U,$J,358.3,18557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18557,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,18557,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,18557,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,18558,0)
 ;;=E89.1^^94^908^49
 ;;^UTILITY(U,$J,358.3,18558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18558,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,18558,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,18558,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,18559,0)
 ;;=H40.9^^94^909^9
 ;;^UTILITY(U,$J,358.3,18559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18559,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,18559,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,18559,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,18560,0)
 ;;=H26.9^^94^909^5
 ;;^UTILITY(U,$J,358.3,18560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18560,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,18560,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,18560,2)
 ;;=^5005363
 ;;^UTILITY(U,$J,358.3,18561,0)
 ;;=H10.9^^94^909^8
 ;;^UTILITY(U,$J,358.3,18561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18561,1,3,0)
 ;;=3^Conjunctivitis,Unspec
 ;;^UTILITY(U,$J,358.3,18561,1,4,0)
 ;;=4^H10.9
 ;;^UTILITY(U,$J,358.3,18561,2)
 ;;=^5004716
 ;;^UTILITY(U,$J,358.3,18562,0)
 ;;=H11.32^^94^909^6
 ;;^UTILITY(U,$J,358.3,18562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18562,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Left Eye
 ;;^UTILITY(U,$J,358.3,18562,1,4,0)
 ;;=4^H11.32
 ;;^UTILITY(U,$J,358.3,18562,2)
 ;;=^5004783
 ;;^UTILITY(U,$J,358.3,18563,0)
 ;;=H11.31^^94^909^7
 ;;^UTILITY(U,$J,358.3,18563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18563,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Right Eye
 ;;^UTILITY(U,$J,358.3,18563,1,4,0)
 ;;=4^H11.31
 ;;^UTILITY(U,$J,358.3,18563,2)
 ;;=^5004782
 ;;^UTILITY(U,$J,358.3,18564,0)
 ;;=H01.002^^94^909^3
 ;;^UTILITY(U,$J,358.3,18564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18564,1,3,0)
 ;;=3^Blepharitis Unspec,Right Lower Eyelid
 ;;^UTILITY(U,$J,358.3,18564,1,4,0)
 ;;=4^H01.002
 ;;^UTILITY(U,$J,358.3,18564,2)
 ;;=^5004239
